219 related articles for article (PubMed ID: 37322842)
1. Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.
Bachert C; Laidlaw TM; Cho SH; Mullol J; Swanson BN; Naimi S; Classe M; Harel S; Jagerschmidt A; Laws E; Ruddy M; Praestgaard A; Amin N; Mannent LP
Ann Otol Rhinol Laryngol; 2023 Dec; 132(12):1649-1661. PubMed ID: 37322842
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics.
Busse WW; Pavord ID; Siddiqui S; Khan AH; Praestgaard A; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2023; 16():411-419. PubMed ID: 37096015
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Hamilton JD; Harel S; Swanson BN; Brian W; Chen Z; Rice MS; Amin N; Ardeleanu M; Radin A; Shumel B; Ruddy M; Patel N; Pirozzi G; Mannent L; Graham NMH
Clin Exp Allergy; 2021 Jul; 51(7):915-931. PubMed ID: 34037993
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.
Lee SE; Hopkins C; Mullol J; Msihid J; Guillemin I; Amin N; Mannent LP; Li Y; Siddiqui S; Chuang CC; Kamat S; Khan AH
Allergy; 2022 Jul; 77(7):2211-2221. PubMed ID: 35034364
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
[No Abstract] [Full Text] [Related]
9. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the SINUS-52 trial.
Fokkens WJ; Bachert C; Hopkins C; Marglani O; Praestgaard A; Nash S; Deniz Y; Rowe PJ; Sacks H; Jacob-Nara JA
Clin Transl Immunology; 2024; 13(6):e1511. PubMed ID: 38854740
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
Schneider S; Poglitsch K; Morgenstern C; Quint T; Gangl K; Sinz C; Bartosik T; Campion NJ; Liu DT; Landegger LD; Tu A; Stanek V; Rocha-Hasler M; Bangert C; Eckl-Dorna J
Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36549708
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma.
Gurnell M; Radwan A; Bachert C; Lugogo N; Cho SH; Nash S; Zhang H; Khan AH; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2024; 17():1-8. PubMed ID: 38250137
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
Fujieda S; Matsune S; Takeno S; Ohta N; Asako M; Bachert C; Inoue T; Takahashi Y; Fujita H; Deniz Y; Rowe P; Ortiz B; Li Y; Mannent LP
Allergy; 2022 Jan; 77(1):186-196. PubMed ID: 33993501
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
Hoy SM
Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
[TBL] [Abstract][Full Text] [Related]
17. Real-Life Study of Patient Preference for Dupilumab or Revision Surgery for Recurrent Chronic Rhinosinusitis with Nasal Polyps.
Gangl K; Liu DT; Bartosik T; Campion NJ; Vyskocil E; Mueller CA; Knerer B; Eckl-Dorna J; Schneider S
J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672965
[TBL] [Abstract][Full Text] [Related]
18. Biologics Reduce Symptoms of Alcohol Intolerance Better than Aspirin Desensitization in Patients with N-ERD and Nasal Polyps.
Foerster-Ruhrmann U; Jurkov M; Szczepek AJ; Bergmann KC; Fluhr JW; Olze H
Biomedicines; 2024 May; 12(5):. PubMed ID: 38790987
[TBL] [Abstract][Full Text] [Related]
19. Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab.
Ledda AG; Costanzo G; Sambugaro G; Caruso C; Bullita M; Di Martino ML; Serra P; Firinu D; Del Giacco S
Life (Basel); 2023 Sep; 13(9):. PubMed ID: 37763288
[TBL] [Abstract][Full Text] [Related]
20. The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids.
Bartosik TJ; Campion NJ; Freisl K; Liu DT; Gangl K; Stanek V; Tu A; Pjevac P; Hausmann B; Eckl-Dorna J; Schneider S
Front Immunol; 2023; 14():1112345. PubMed ID: 37122714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
